Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11612358 | 0.85 | CA2 (0.40) | CA2CA1CA9 | |
| SCHEMBL21312124 | 0.85 | CA1 (0.36) | CA2CA1CA9 | |
| SCHEMBL4813050 | 0.85 | CA2 (0.36) | CA2CA1CA9 | |
| SCHEMBL3242894 | 0.85 | CA2 (0.36) | CA2CA1CA9 | |
| SCHEMBL20602111 | 0.81 | CA2 (0.34) | CA2CA1CA9 | |
| SCHEMBL18896075 | 0.81 | CA2 (0.34) | CA2CA1CA9 | |
| SCHEMBL17858943 | 0.79 | CA2 (0.33) | CA2CA1CA9 | |
| SCHEMBL3241936 | 0.79 | CA2 (0.33) | CA2CA1CA9 | |
| SCHEMBL1855129 | 0.79 | CA2 (0.39) | CA2CA1CA9 | |
| SCHEMBL26912 | 0.79 | CA2 (0.56) | CA2CA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 283 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11672785-B2 | Tetrahydro-1H-pyrido [3,4-b]indole anti-estrogenic drugs | OLEMA PHARMACEUTICALS, INC. (US) | 2023-06-13 | — | — | US | claimed |
| US-20220370421-A1 | TETRAHYDRO-1H-PYRIDO [3,4-b]INDOLE ANTI-ESTROGENIC DRUGS | OLEMA PHARMACEUTICALS, INC. | 2022-11-24 | — | — | US | claimed |
| US-20260144778-A1 | REGIMENS OF ESTROGEN RECEPTOR ANTAGONISTS | OLEMA PHARMACEUTICALS, INC. (US) | 2026-05-28 | — | — | US | disclosed |
| EP-4736854-A2 | HETEROCYCLIC COMPOUNDS AS MODULATORS OF BCL6 AS LIGAND DIRECTED DEGRADERS | Bristol-Myers Squibb Company (US) | 2026-05-06 | — | — | EP | disclosed |
| US-12606541-B2 | PPARg modulators and methods of use | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2026-04-21 | — | — | US | disclosed |
| US-20260103461-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | OLEMA PHARMACEUTICALS INC (US) | 2026-04-16 | — | — | US | disclosed |
| EP-4514473-B1 | HETEROCYCLIC COMPOUNDS AS MODULATORS OF BCL6 AS LIGAND DIRECTED DEGRADERS | BRISTOL MYERS SQUIBB CO (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20260028341-A1 | IMIDAZOTRIAZINE DERIVATIVES AS IL-17 MODULATORS | UCB Biopharma SRL (BE) | 2026-01-29 | — | — | US | disclosed |
| US-20260007681-A1 | INDOLE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | UNIV MICHIGAN (US) | 2026-01-08 | — | — | US | disclosed |
| US-20250368625-A1 | PIPERAZINES | Grünenthal GmbH (DE) | 2025-12-04 | — | — | US | disclosed |
| US-20250320183-A1 | Modulators of BCL6 as Ligand Directed Degraders | CELGENE CORPORATION (US) | 2025-10-16 | — | — | US | disclosed |
| US-20100087429-A1 | SPIRO-TRICYCLIC RING COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2010-04-08 | — | — | US | disclosed |
| WO-2010030954-A1 | SPIRO-TETRACYCLIC RING COMPOUNDS AS BETASECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2010-03-18 | — | — | WO | disclosed |
| US-20090264445-A1 | PYRROLIDINONE GLUCOKINASE ACTIVATORS | BERTHEL STEVEN JOSEPH | 2009-10-22 | — | — | US | disclosed |
| WO-2009127546-A1 | PYRROLIDINONE GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-10-22 | — | — | WO | disclosed |
| EP-2091928-A2 | 3-(2-ACYLAMINO-1-HYDROXYETHYL)- MORPHOLINE DERIVATIVES AND THEIR USE AS BACE INHIBITORS | ELI LILLY AND COMPANY (US) | 2009-08-26 | — | — | EP | disclosed |
| US-7429674-B2 | Process for preparing fluoroleucine alkyl esters | MERCK & CO. INC.. (US) | 2008-09-30 | — | — | US | disclosed |
| US-7429674-B2 | Process for preparing fluoroleucine alkyl esters | MERCK & CO. INC.. (US) | 2008-09-30 | — | — | US | disclosed |
| US-20070225267-A1 | 3-(2-Acylamino-1-Hydroxyethyl)-Morpholine Derivatives and Their Use as Bace Inhibitors | ELI LILLY AND COMPANY | 2007-09-27 | — | — | US | disclosed |
| WO-2006034093-A2 | 3- (2-ACYLAMINO-1-HYDROXYETHYL)- MORPHOLINE DERIVATIVES AND THEIR USE AS BACE INHIBITORS | ELLI LILLY AND COMPANY (US) | 2006-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11672785-B2 | Tetrahydro-1H-pyrido [3,4-b]indole anti-estrogenic drugs | ESR1, CYP19A1, HSD17B11 | CA2 1896/4885CA1 1198/4885CA9 3028/4885 |
| US-20260103461-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ESRRA, GPER1, ESR2 | CA2 699/4885CA1 745/4885CA9 1354/4885 |
| US-20070225267-A1 | 3-(2-Acylamino-1-Hydroxyethyl)-Morpholine Derivatives and Their Use as Bace Inhibitors | BACE1, BACE2, APP | CA2 2660/4885CA1 1464/4885CA9 3327/4885 |
| US-20090264445-A1 | PYRROLIDINONE GLUCOKINASE ACTIVATORS | GCKR, GCK, PDK2 | CA2 2535/4885CA1 4305/4885CA9 2829/4885 |
| US-20260028341-A1 | IMIDAZOTRIAZINE DERIVATIVES AS IL-17 MODULATORS | IL17A, IL6ST, IL6 | CA2 1939/4885CA1 2509/4885CA9 3345/4885 |
| US-20260007681-A1 | INDOLE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ESRRA, ESR2, AR | CA2 871/4885CA1 1137/4885CA9 772/4885 |
| US-20250320183-A1 | Modulators of BCL6 as Ligand Directed Degraders | BCL6, BCL6B, BCL3 | CA2 4634/4885CA1 3464/4885CA9 3422/4885 |
| US-12606541-B2 | PPARg modulators and methods of use | PPARG, PPARA, PPARD | CA2 2393/4885CA1 4704/4885CA9 3899/4885 |
| US-20100087429-A1 | SPIRO-TRICYCLIC RING COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | BACE1, BACE2, APP | CA2 2229/4885CA1 85/4885CA9 3008/4885 |
| US-20250368625-A1 | PIPERAZINES | SSTR4, SSTR5, SSTR2 | CA2 1871/4885CA1 3396/4885CA9 3944/4885 |
| US-20220370421-A1 | TETRAHYDRO-1H-PYRIDO [3,4-b]INDOLE ANTI-ESTROGENIC DRUGS | ESR1, CYP19A1, HSD17B11 | CA2 1896/4885CA1 1198/4885CA9 3028/4885 |
| US-20260144778-A1 | REGIMENS OF ESTROGEN RECEPTOR ANTAGONISTS | ESR1, ESR2, PGR | CA2 2973/4885CA1 4038/4885CA9 3077/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.